Although snoring is common in the general population, its aetiology has been largely understudied. Here we report a genetic study on snoring (n~408,000; snorers~152,000) using data from the UK Biobank. We identify 42 genome-wide significant loci, with an SNPbased heritability estimate of~10% on the liability scale. Genetic correlations with body mass index, alcohol intake, smoking, schizophrenia, anorexia nervosa and neuroticism are observed. Gene-based associations identify 173 genes, including DLEU7, MSRB3 and POC5, highlighting genes expressed in the brain, cerebellum, lungs, blood and oesophagus. We use polygenic scores (PGS) to predict recent snoring and probable obstructive sleep apnoea (OSA) in an independent Australian sample (n~8000). Mendelian randomization analyses suggest a potential causal relationship between high BMI and snoring. Altogether, our results uncover insights into the aetiology of snoring as a complex sleep-related trait and its role in health and disease beyond it being a cardinal symptom of OSA.
The bidirectional relationship between depression and chronic pain is well-recognized, but their clinical management remains challenging. Here we characterize the shared risk factors and outcomes for their comorbidity in the Australian Genetics of Depression cohort study (N = 13,839). Participants completed online questionnaires about chronic pain, psychiatric symptoms, comorbidities, treatment response and general health. Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors. Cumulative linked logistic regressions assessed the effect of chronic pain on treatment response for 10 different antidepressants. Chronic pain was associated with an increased risk of depression (OR = 1.86 [1.37–2.54]), recent suicide attempt (OR = 1.88 [1.14–3.09]), higher use of tobacco (OR = 1.05 [1.02–1.09]) and misuse of painkillers (e.g., opioids; OR = 1.31 [1.06–1.62]). Participants with comorbid chronic pain and depression reported fewer functional benefits from antidepressant use and lower benefits from sertraline (OR = 0.75 [0.68–0.83]), escitalopram (OR = 0.75 [0.67–0.85]) and venlafaxine (OR = 0.78 [0.68–0.88]) when compared to participants without chronic pain. Furthermore, participants taking sertraline (OR = 0.45 [0.30–0.67]), escitalopram (OR = 0.45 [0.27–0.74]) and citalopram (OR = 0.32 [0.15–0.67]) specifically for chronic pain (among other indications) reported lower benefits compared to other participants taking these same medications but not for chronic pain. These findings reveal novel insights into the complex relationship between chronic pain and depression. Treatment response analyses indicate differential effectiveness between particular antidepressants and poorer functional outcomes for these comorbid conditions. Further examination is warranted in targeted interventional clinical trials, which also include neuroimaging genetics and pharmacogenomics protocols. This work will advance the delineation of disease risk indicators and novel aetiological pathways for therapeutic intervention in comorbid pain and depression as well as other psychiatric comorbidities.
Study Objective Sleep is essential for both physical and mental health, and there is a growing interest in understanding how different factors shape individual variation in sleep duration, quality and patterns, or confer risk for sleep disorders. The present study aimed to identify novel inferred causal relationships between sleep-related traits and other phenotypes, using a genetics-driven hypothesis-free approach not requiring longitudinal data. Methods We used summary-level statistics from genome-wide association studies and the latent causal variable (LCV) method to screen the phenome and infer causal relationships between seven sleep-related traits (insomnia, daytime dozing, easiness of getting up in the morning, snoring, sleep duration, napping, and morningness) and 1,527 other phenotypes. Results We identify 84 inferred causal relationships. Among other findings, connective tissue disorders increase insomnia risk and reduce sleep duration; depression-related traits increase insomnia and daytime dozing; insomnia, napping and snoring are affected by obesity and cardiometabolic traits and diseases; and working with asbestos, thinner, or glues may increase insomnia risk, possibly through an increased risk of respiratory disease or socio-economic related factors. Conclusion Overall, our results indicate that changes in sleep variables are predominantly the consequence, rather than the cause, of other underlying phenotypes and diseases. These insights could inform the design of future epidemiological and interventional studies in sleep medicine and research.
Study Objective. Sleep is essential for both physical and mental health.There is an increasing interest in understanding how different factors shape individual variation in sleep duration, quality and patterns, or confer risk for sleep disorders. The present study aimed to identify novel causal relationships between sleep-related traits and other phenotypes, using a genetics-driven hypothesis-free approach not requiring longitudinal data. Methods. We used genetic data and the latent causal variable (LCV) method to screen the phenome and infer causal relationships between seven sleep-related traits (insomnia, daytime dozing, easiness of getting up in the morning, snoring, sleep duration, napping, and morningness) and 1,527 different phenotypes. Results. We identify 84 significant causal relationships. Among other findings, poor health of musculoskeletal and connective tissue disorders increase insomnia risk and reduce sleep duration; depression-related traits increase insomnia and daytime dozing; insomnia, napping and snoring are affected by obesity and cardiometabolic traits and diseases; and working with asbestos, thinner, or glues increases insomnia, potentially through an increased risk of respiratory disease. Conclusion. Overall, our results indicate that changes in sleep variables are predominantly the consequence, rather than the cause, of other underlying phenotypes and diseases. These insights could inform the design of future epidemiological and interventional studies in sleep medicine and research.
Rationale: Sleep apnoea is a complex disorder characterised by periods of halted breathing during sleep. Despite its association with serious health conditions such as cardiovascular disease, the aetiology of sleep apnoea remains understudied, and previous genetic studies have failed to identify replicable genetic risk factors. Objective: To advance our understanding of factors that increase susceptibility to sleep apnoea by identifying novel genetic associations. Methods: We conducted a genome-wide association study (GWAS) meta-analysis of sleep apnoea across five cohorts, and a previously published GWAS of apnoea-hypopnea index (N Total =510,484). Further, we used multi-trait analysis of GWAS (MTAG) to boost statistical power, leveraging the high genetic correlations between apnoea, snoring and body mass index. Replication was performed in an independent sample from 23andMe, Inc (N Total =1,477,352; N cases =175,522). Results: Our results revealed 39 independent genomic loci robustly associated with sleep apnoea risk, and significant genetic correlations with multisite chronic pain, sleep disorders, diabetes, high blood pressure, osteoarthritis, asthma and BMI-related traits. We also derived polygenic risk scores for sleep apnoea in a leave-one-out independent cohort and predicted probable sleep apnoea in participants (OR=1.15 to 1.22; variance explained = 0.4 to 0.9%). Conclusions: We report novel genetic markers robustly associated with sleep apnoea risk and substantial molecular overlap with other complex traits, thus advancing our understanding of the underlying biological mechanisms of susceptibility to sleep apnoea.
Background: The bidirectional relationship between depression and chronic pain is well recognized but their clinical management remains challenging. Here we characterize the shared aetiology and risk factors for their comorbidity using large population cohorts to advance understanding of pharmacological treatment outcomes. Methods: Participants completed online questionnaires about chronic pain, psychiatric symptoms, comorbidities, treatment response and general health (N=13,839). Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors. Cumulative linked logistic regressions assessed the effect of chronic pain on treatment response for 10 different antidepressants. Findings: Chronic pain was associated with an increased risk of depression (OR=1.86 [1.37-2.54]), recent suicide attempt (OR=1.88[1.14-3.09]), higher use of alcohol, tobacco and painkiller misuse. Participants with comorbid chronic pain and depression reported fewer functional benefits from antidepressant use and lower benefits from sertraline (OR=0.75[0.68-0.83]), escitalopram (OR=0.75[0.67-0.85]) and venlafaxine (OR=0.78[0.68-0.88]) when compared to participants without chronic pain. Furthermore, participants taking sertraline (OR=0.45[0.30-0.67]), escitalopram (OR=0.45[0.27-0.74]) and citalopram (OR=0.32[0.15-0.67]) specifically for chronic pain reported lower benefits compared to other participants taking these same medications but not for chronic pain. Interpretation: The findings reveal novel insights into the complex relationship between chronic pain and depression. Treatment response analyses indicate differential effectiveness between particular antidepressants and poorer functional outcomes for these comorbid conditions. Further assessment is warranted in targeted interventional trials. This approach will advance precision psychiatry and assist in clinical management by choosing the most suitable treatment for patients, informed by specific symptoms and comorbidities.
Background Migraine is a complex neurological disorder that is considered the most common disabling brain disorder affecting 14 % of people worldwide. The present study sought to infer potential causal relationships between self-reported migraine and other complex traits, using genetic data and a hypothesis-free approach. Methods We leveraged available summary statistics from genome-wide association studies (GWAS) of 1,504 phenotypes and self-reported migraine and inferred pair-wise causal relationships using the latent causal variable (LCV) method. Results We identify 18 potential causal relationships between self-reported migraine and other complex traits. Hypertension and blood clot formations were causally associated with an increased migraine risk, possibly through vasoconstriction and platelet clumping. We observed that sources of abdominal pain and discomfort might influence a higher risk for migraine. Moreover, occupational and environmental factors such as working with paints, thinner or glues, and being exposed to diesel exhaust were causally associated with higher migraine risk. Psychiatric-related phenotypes, including stressful life events, increased migraine risk. In contrast, ever feeling unenthusiastic / disinterested for a whole week, a phenotype related to the psychological well-being of individuals, was a potential outcome of migraine. Conclusions Overall, our results suggest a potential vascular component to migraine, highlighting the role of vasoconstriction and platelet clumping. Stressful life events and occupational variables potentially influence a higher migraine risk. Additionally, a migraine could impact the psychological well-being of individuals. Our findings provide novel testable hypotheses for future studies that may inform the design of new interventions to prevent or reduce migraine risk and recurrence.
, Nicholas G.Martin (0000-0003-4069-8020), Gabriel Cuéllar-Partida (0000-0001-7648-4097), Miguel E. Rentería (0000- 0003-4626-7248). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.